Background: Cardiovascular diseases (CVD) represent a major health issue in patients with schizophrenia and bipolar disorder (BD), but the underlying mechanisms remain unclear.
approach.
PRS was first proposed by Purcell et al.(17) to study the polygenic basis of schizophrenia and its shared genetic basis with bipolar affective disorder. It has increasingly been used in recent years to a variety of complex diseases (18) . We made use of large-scale GWAS meta-analyses results for schizophrenia, BD and a comprehensive panel of metabolic and cardiovascular traits to construct polygenic scores. We employed the statistical approach in the R package gtx (19) for association testing, using pairs of summary results as input. We also examined PRS associations with cardiovascular risk factors in the Northern Finland Birth Cohort with individual genotype and phenotype data.
After studying the overall sharing of genetic risks, we "zoomed in" to discover the genetic variants shared between schizophrenia and BD with each metabolic trait, and inferred the likely pathways involved by gene-set analyses.
In a related work, Andreassen et al. (20) proposed a conditional false discovery rate approach to identify loci associated with both schizophrenia and CVD risk factors, with an aim to improving gene discovery in schizophrenia. In the current work we took a different and more comprehensive approach. Compared to the study by Andreassen et al., we employed a methodology based on PRS to assess overall genetic sharing. We also studied the genetic sharing of cardiometabolic risks with bipolar disorder, a topic not investigated before. A much wider range of metabolic parameters and diseases were included. The sample size of schizophrenia GWAS in this study reaches ~82000, which is about four times the size of the previous one (21) . In addition, we looked into the directions of associations in this study which was not investigated previously (20) .
To our knowledge, this is the first systemic study on the shared genetic bases of cardiometabolic traits with both schizophrenia and BD using PRS, and the first to uncover shared genetic variants between BD and cardiometabolic diseases with large-scale GWAS data.
Materials and methods

Derivation of polygenic risk scores (PRS)
PRS are derived from the summary statistics of GWAS meta-analyses, obtained from the Psychiatric Genomics Consortium website (https://www.med.unc.edu/pgc). We obtained the summary results of schizophrenia (22) , BD (15) , low-density lipoprotein (LDL), high-density lipoprotein (HDL), total cholesterol (TC), triglycerides (TG) (23) , body mass index (BMI) (24) , fasting glucose (FG) (25) , fasting insulin (INS) (25) , waist-hip ratio (WHR) (26) , type II diabetes mellitus (DM) (27) and coronary artery disease (CAD) (28) . For FG, INS and WHR, we obtained the summary statistics both with and without adjustment for BMI. Details of individual studies are given in the above references. Summary statistics for blood pressure (29) were included for shared SNP analyses. However as the data file does not specify the reference or risk allele, PRS association analysis was not performed.
The PRS is derived from a weighted sum of allelic counts, with the weights given by log odds ratios of individual genetic variants. The PRS for an individual i (r i ) can be denoted as
where ij
x is the (centered) allelic count for the jth SNP for the ith individual, j w is the weight given to the jth SNP, given by the log odds ratio or regression coefficient in a linear regression. We employed two approaches for PRS testing. In the first approach, only the summary statistics of each pair of traits are used. Association testing was carried out by the method gtx described by Johnson (19) . This method was also described in a number of papers (30) (31) (32) . Briefly, we tested for the association of the PRS derived from the first trait with a second trait i y (with values centered) by regression:  . In order to investigate the bi-directional effects of polygenic risk of schizophrenia and BD on metabolic traits, we performed two sets of analyses, one using PRS from the psychiatric disorders to regress on metabolic traits and the other using PRS from metabolic traits to regress on schizophrenia or BD.
Polygenic risk score testing in the Northern Finland Birth Cohort 1966
In the second approach, PRS testing was performed on individual genotype and phenotype data in the Northern Finland Birth Cohort (NFBC) 1966. The raw genotype and phenotype data was accessed from dbGaP (accession number phs000276.v2.p1). The original study has passed all relevant ethnical approvals. All study subjects were recruited from Norther Finland and all traits in this study were measured at 31 years old. GWAS has been performed on this cohort using the Infinium 370cnvDuo array (33) . We included a range of metabolic traits in our analyses, including TG, HDL, LDL, BMI, WHR, FG, INS, systolic blood pressure (SBP) and diastolic blood pressure (DBP).
Standard GWAS quality control procedures were performed. Genetic variants with missing rate >10%, minor allele frequency <0.01 and with significant deviation from Hardy-Weinberg equilibrium (p<10 -5 ) were excluded. Individuals with genotyping rates <90% were excluded from analyses. We also excluded individuals who are pregnant, receiving anti-diabetic medications, or not fasted before blood glucose and lipid measurements. After the above filtering and quality control procedures, 4982 individuals and 334458 SNPs were retained for further analyses.
Linear regression was carried out to test for the association of PRS with each of the metabolic traits. We included gender and the top ten principal components (PCs) derived from GWAS data as covariates (34) . The analyses were repeated with and without BMI as a covariate.
PRS analyses were performed by the R program PRsice (35) . Linkage disequilibrium (LD) clumping was performed prior to polygenic scoring. This procedure preferentially selects markers with lower p-value while pruning out variants having a certain degree of LD with the selected ones. We used an R 2 threshold of 0.25 for testing PRS associations in the NFBC sample. The method gtx however requires a stronger assumption on the independence between SNPs, and we chose an R 2 threshold of 0.05, following the suggestions given in the PRsice vignette. We used the 1000 Genome Project sample as reference LD panel for gtx analyses.
Polygenic scores were calculated over a range of p-value thresholds (0.01, 0.03, 0.05, 0.1, 0.3 and 0.5).
Multiple testing was corrected by the false discovery rate (FDR) procedure, which controls for the expected proportion of false positives. The R program p.adjust was used to compute the corresponding FDR for every hypothesis test, which is also known as the q-value (the proportion of null was set to be one in all calculations). A q-value smaller than 0.05 is regarded as significant.
Discovering shared SNPs
For each pair of diseases (psychiatric versus metabolic), we computed for every SNP the probability of being associated with both diseases, given the observed test statistics. It can be viewed as a two-dimensional extension of the local true discovery rate (36) . The approach is related to the conditional false discovery rate (20) but here we focused on the chance of shared associations instead of probability of association conditioned on another trait. A similar methodology was also proposed by Chung et al. (37) , but here we worked with the z-statistics instead of p-values. Briefly, we assumed a four-group mixture model of z-statistics: 00 00 10 10 01 01 11 11
where z A and z B refer to the z-statistics of trait A and trait B respectively. There are four possibilities for each SNP when two traits are considered: 1) the SNP is associated with none of the traits; (2) the SNP is associated with the first trait only; (3) the SNP is associated with the second trait only; and (4) the SNP is associated with both traits. Each of these four possibilities are represented in the above mixture model. For instance, p 11 denotes the proportion of markers that has association with both traits, and f 11 denotes the probability density function of the z-statistics of this group of markers. From equation (1) we can derive the probability that a SNP is associated with both traits (denoted by tdr 11 ), using an expectation-maximization (EM) algorithm. Further details of the method are given in Supplementary Information. Note that for the shared SNP analyses, we also included systolic blood pressure and diastolic blood pressure (29) , as the shared SNP analysis does not require signs of the test statistics to be specified.
Pathway analysis
We selected SNPs with tdr 11 >= 0.5 and tdr 11 >=0.8 and mapped those SNPs to genes using the Bioconductor package BioMart using default settings. We noted that some SNPs were mapped to multiple genes which may bias the results of gene set analyses. We adopted the following method to correct for this bias. We first extracted information on variant consequences (using with the lowest p-values in the PRS analyses, we also repeated pathway analyses for SNPs showing the same direction of association as in the PRS analyses.
Results
Schizophrenia and cardiometabolic traits
The associations of schizophrenia with cardiometabolic traits using paired summary statistics are shown in Table 1 and Supplementary Tables 1 and 2 . First PRS are constructed from metabolic traits and schizophrenia was treated as the outcome (i.e. target phenotype).
Intuitively, PRS from the metabolic traits can be regarded as a proxy of the actual level of the trait and a previous study (38) has shown that such a polygenic scoring approach can be used to test association of biomarkers with disease. For binary traits, the polygenic scores may be regarded as the underlying liability to the corresponding disorder.
The strongest associations were observed for CAD (p = 3.93E-99), DM (p = 8.38E-09) and BMI (p = 9.34E-13). Polygenic scores of CAD and DM are positively associated with schizophrenia, while an inverse association was observed for BMI. On the other hand, WHR showed a positive relationship with schizophrenia, and the result became more significant after controlling for BMI (p = 3.99E-05).
As for traits related to glucose metabolism, besides DM, FG showed the strongest association with schizophrenia (p = 0.00641), and insulin levels were also positively associated, but the significance was weaker (p = 0.0139). BMI adjustment slightly attenuated the results.
As for lipid traits, lower polygenic scores of LDL, TC and TG and a higher polygenic score of HDL were associated with schizophrenia.
When polygenic score of schizophrenia was used as a predictor variable and metabolic traits as outcomes, the strongest associations were again seen for BMI (p = 5.59E-11), CAD (p = 5.03E-83) and DM (p = 1.25E-54). The regression coefficient for CAD was 2.67E-2, which corresponds to an odds ratio (OR) of exp(2.67E-02) = 1.03 if we assume an approximation of the logistic regression by a linear model (39) . This may be roughly interpreted as an increase in CAD risk by ~3% for every unit increase in the schizophrenia polygenic score. Similarly, we observed an approximately 5% increased risk for DM for every unit increase of schizophrenia PRS. Association results for HDL and WHR (adjusted for BMI) were also highly significant, while other traits showing mostly nominal or non-significant associations with q-values greater than 0.05.
For analyses on the Northern Finland Birth Cohort, the most significant association was WHR adjusted for BMI (p = 0.00542) ( Table 2 and Supplementary Tables 5-6 ). Other results were largely non-significant, probably owing to a much smaller sample size of NFBC compared to the GWAS meta-analyses.
The results of the shared SNPs analyses with tdr 11 >0.5 and tdr 11 >0.8 are presented in Table 5 and Supplementary Tables 9 and 11 . The full results of pathway analyses are presented in Supplementary Tables 13-16 Table 3 and Supplementary Tables 3-4 showed the associations of BD with cardiometabolic traits using paired summary statistics. Similar to schizophrenia, the strongest associations were observed for BMI (p = 9.34E-13), CAD (p = 2.83E-23) and DM (p = 2.20E-18) when BD was treated as the target phenotype. We again observed an inverse relationship between BMI and BD, while polygenic scores of CAD and DM are positively related to BD. The next most significant result was an association of lower WHR with BD (p = 1.35E-03), but the result became non-significant after adjustment by BMI, suggesting the original association is mainly driven by BMI. A few other results also reached nominal significance (p < 0.05), including inverse relationships of LDL with BD (p = 0.020 and 0.028 respectively when BD was the target and base phenotype respectively), and associations of BD polygenic risks with higher BMI-adjusted FG and INS. As for the analyses results for NFBC cohort, we observed a nominally significant inverse association with BMI, but no other significant associations (Table   4 , Supplementary Tables 7 and 8 ).
Bipolar disorder and cardiometabolic traits
The results of the shared SNPs analyses are presented in Table 6 and Supplementary   Tables 10 and 12. Supplementary Tables 17-20 show the full results of gene set analyses. As GWAS sample size for BD is smaller, the number of shared SNPs with high tdr 11 was smaller.
Tables 7-8 list the top ten enriched pathways for CAD and DM (shown in full in Supplementary Tables 24-26 ). For CAD, many of the top pathways were related to lipid or lipoprotein metabolism. For BD and DM, the top pathways included complement activation and extra-cellular matrix components.
Discussion
We have performed polygenic risk score ansalyses on the possible shared genetic basis of schizophrenia and BD with a comprehensive panel of cardiometabolic traits. We discovered a number of significant associations, which we shall discuss in the following sections.
Schizophrenia and cardiometabolic traits
The most remarkable finding is the strong polygenic associations of schizophrenia with both DM and CAD. Raised cardiovascular morbidity and mortality is well-established in schizophrenia, yet it is difficult to disentangle the numerous possible underlying factors, including the side-effects of antipsychotics. We found that polygenic risks (or genetic liabilities) of schizophrenia are associated with CAD and DM, and vice versa. Such a relationship has not been discovered from studies of drug-naïve subjects, as the patients were usually young and the number of DM and CAD cases was too small to achieve statistical power. To our knowledge, this is also the first study to show a shared genetic basis of schizophrenia with coronary heart disease. In line with a genetic propensity to developing diabetes, we also observed higher polygenic scores of FG in schizophrenia. It is notable that multiple studies have found impaired glucose tolerance or insulin resistance in drug-naïve patients and their first-degree relatives (13, (40) (41) (42) (43) (44) (45) .
Despite increased cardiovascular risks in schizophrenia patients, surprisingly, we found evidence for an inverse relationship between polygenic scores of BMI and schizophrenia.
Interestingly, a population cohort study of over 1 million men in Sweden also reported that subjects with lower BMI had an increased risk of developing schizophrenia (46) . A similar study in Denmark reached the same conclusions (47) . A few studies in drug-naïve patients also revealed a trend of lower BMI. For instance, lower BMI among drug-free schizophrenia patients was reported by Spelman et al. (13) and Pandmavati et al. (48) . However, some studies failed to detect any differences in BMI between schizophrenia cases and controls (40, 41) . The underlying pathophysiology for an inverse relationship between BMI and schizophrenia is unknown. One hypothesis is that poor nutritional status, however subtle, may adversely affect neural development (46) which leads to psychotic disorders.
While we observe that lower BMI polygenic score is associated with schizophrenia and vice versa, we observed the opposite trend for WHR. Polygenic association of higher WHR with schizophrenia, especially after adjustment for BMI, is shown both in the Northern Finland cohort sample and analyses using summary statistics. Consistent with this finding, Ryan et al.
reported higher WHR and three times more intra-abdominal fat in drug-free schizophrenia patients compared to BMI-matched controls (49) . Others (50) (51) also reported increased WHR in drug-free patients compared to controls. While some studies did not find any differences in WHR (40, 52) , they were of small sample sizes and inadequate power may explain the inconsistent results. Waist-hip ratio reflects visceral fat deposition, and has been suggested to be an informative predictor of cardiovascular risks independent of BMI (53, 54) .
Excess visceral adiposity may partially explain the increased risks for DM and CAD despite a tendency of lower BMI. However it is also possible that some shared genetic factors may specifically increase the risks of DM and CAD without major effects on lipid levels, body weight or other known CV risk factors.
For lipid traits, we observed schizophrenia patients tend to have lower polygenic scores of LDL but higher HDL levels. It is possible that such relationships are related to lower BMI in schizophrenia subjects. However as BMI-adjusted GWAS meta-analyses for lipid traits are not available, we did not directly test this hypothesis in our analyses with summary statistics. We did not find associations with lipid levels in the NFBC sample. Two previous clinical studies on drug-naïve patients had found significantly lower TC and LDL (40, 42) , while others failed to find any associations
Bipolar disorder and cardiometabolic traits
Similar to schizophrenia, we found that higher polygenic risks of CAD and DM are associated with BD, suggesting a shared genetic basis of BD with CAD or DM. To our knowledge, this is the first report on a polygenic overlap among the disorders. On the other hand, we observed an inverse genetic relationship between BMI and BD. One previous clinical study reported a higher prevalence of being overweight among bipolar patients (55) . However, the weight measurements were not made during euthymic period and 71.4% of the patients were depressed during the measurement. It is possible that the symptoms of bipolar depression contributed to the findings. As remarked by the authors, their findings might be more related to the current episode of illness than to the underlying disorder (55) . Given that schizophrenia and BD are highly genetically correlated (15) , it may not be surprising that a similar inverse relationship exists between polygenic scores of BMI and BD. While WHR was also inversely related to BD in the unadjusted analysis, the relationship no longer exists after controlling for BMI.
There are very few studies on the metabolic parameters in drug-naive bipolar patients in comparison with healthy controls. Guha et al. (14) reported higher fasting glucose and insulin in drug naive patients as compared with controls. In line with this finding, we observed that BD polygenic score are possibly associated with FG and INS, after controlling for BMI. We do not observe evidence of polygenic association of dyslipidemia with BD; on the contrary, there appeared to be an inverse relationship with LDL. This result could be confounded by BMI, although studies have found lower cholesterol level in bipolar patients (56, 57) . There is also evidence of a correlation between low cholesterol levels and suicide risks (58) . The underlying mechanism remains elusive, but it has been suggested that low cholesterol may be associated with decreased lipid microviscosity in neural membranes and reduced exposure of serotonin receptors on membrane surface. Serotonergic dysfunction may in turn contribute to suicidality (59) .
Taken together, we found evidence of genetic predisposition to the development of glucose metabolism abnormalities, DM and CAD in both schizophrenia and BD patients.
Schizophrenia patients are also genetically susceptible to developing central obesity. On the other hand, we observed an inverse relationship between polygenic scores of BMI with both schizophrenia and BD. There is generally no evidence of polygenic associations with dyslipidemia however.
Shared SNP analyses of schizophrenia and bipolar disorder with cardiometabolic traits
We identified a number of susceptibility variants that are potentially shared between schizophrenia or BD and cardiometabolic traits. As the list is long, we will not discuss each susceptibility gene in detail but will highlight a few associated pathways here. For example, it is interesting to note that some shared genes between CAD and schizophrenia or BD are involved in lipid metabolism and the statin pathway. Statins have been known to lower the risk of coronary artery disease (60), yet it has also been investigated as adjunctive therapy for schizophrenia (61) . Vincenzi et al. (61) observed a significant decrease in positive symptoms of schizophrenia patients from baseline to 6 weeks with pravastatin treatment, though the decrease was not significant at 12 weeks. It was postulated that the anti-inflammatory actions of statin contributed to the therapeutic effect on schizophrenia. Note that the anti-inflammatory potential of statins has been postulated as a chief mechanism responsible for preventing CAD (62) .
While we do not observe polygenic scores of schizophrenia or BD to be directly associated with dyslipidemia in this study, it is still possible for genes involved in lipid or lipoprotein metabolism to contribute to CAD risks. The etiology of CAD likely involves the interaction of multiple risk factors; for example, it is possible that polymorphisms in lipid-associated genes act in the presence of other risk factors such as central obesity or hyperglycemia. Also, lipid metabolism can affect cardiovascular risks via other mechanisms, such as interaction with inflammatory pathways. Lipids can activate inflammatory responses which in turn can affect lipid metabolism as well (63) . The increased cardiovascular risks in schizophrenia or bipolar patients may be due to the complex interplay of various biological pathways.
It is interesting to note that pathways associated with immune functioning (e.g. complement pathways, antigen processing and presentation, PD-1 signaling) were ranked highly among some cardiometabolic traits, such as HDL, LDL, TG, DBP and WHR. Immune system dysfunction has been implicated in schizophrenia, BD (64) as well as cardiometabolic traits (65) . Recent studies have suggested that chronic inflammation may be an important mediator linking metabolic abnormalities and severe mental illnesses (66) . For example, elevations of pro-inflammatory cytokines such as tumor necrosis factor alpha and interleukin-6 have been observed both in patients with psychosis and metabolic syndrome. Chronic systemic inflammation may be coupled with microglia activation in the brain, which may disturb neuronal functions (66) . On the other hand, inflammation occurring in visceral adipose tissues, the liver, pancreatic islets and blood vessels contribute to metabolic abnormalities and atherosclerosis (67) . Our findings support a potential role of inflammation and immune system pathways in the shared genetic bases of schizophrenia and BD with cardiometabolic abnormalities.
Clinical implications and study limitations
Our findings provides some evidence to support an increased awareness and better monitoring and management of CVD risks in schizophrenia and BD patients. If our findings are validated in further studies, given that schizophrenia or bipolar patients are at increased CVD risks independent of medication side-effects, proper surveillance and management of cardiovascular risk factors may be required even in patients who are taking drugs with less metabolic side-effects or low-dose medications. In addition, our findings suggested that the measurement of WHR (instead of BMI alone) may be useful in screening for metabolic risks.
There are a few limitations to our study. Our analyses are based on large-scale GWAS meta-analyses results, but most studies were done in Caucasians. It is worthwhile to extend the study to other ethnic groups. For analyses using paired summary results, we were unable to control for other clinical factors, for instance adjusting for WHR when studying CAD risks.
Further studies of metabolic abnormalities in schizophrenia and bipolar patients, coupled with genetic testing, will be useful in delineating the susceptibility markers and providing more solid evidence of shared genetic susceptibilities. While we have discussed a few pathways that may be involved in the shared pathophysiology, further experimental studies are required to elucidate the exact mechanisms involved. Many other shared SNPs and pathways also warrant further investigations. Interestingly, we do not find uniformly increased polygenic risks of all metabolic abnormalities in schizophrenia and BD. Further investigations into the complex links between CVD risk factors and schizophrenia and BD might shed light on new therapeutic measures for both types of disorders.
Conclusions
The current study suggests a shared genetic basis of schizophrenia and BD with numerous cardiometabolic traits. Our findings suggest that heightened cardiovascular risks seen in schizophrenia and bipolar patients might be partially attributed to genetic factors, and psychiatric medications alone may not be the only culprit. Pathway analyses of the shared SNPs reveal that inflammation or immune-related pathways are often over-represented, but many other shared SNPs or pathways are also revealed which warrant further studies.
Increased awareness and proper management of cardiovascular risk factors are crucial to reduce the associated morbidities and mortalities in schizophrenia and BD patients.
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